The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

被引:766
作者
Fischer, JS
Rudick, RA
Cutter, GR
Reingold, SC
机构
[1] Cleveland Clin Fdn, Mellen Ctr U10, Cleveland, OH 44195 USA
[2] AMC Canc Res Ctr, Ctr Res Methodol & Biometr, Lakewood, CO 80214 USA
[3] Natl MS Soc, Res Programs Dept, New York, NY 10017 USA
关键词
multiple sclerosis; clinical trials; clinical outcome assessment; MS Functional Composite (MSFC);
D O I
10.1177/135245859900500409
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales such as the EDSS are inadequate in their assessment of key clinical dimensions of PAS (e.g, cognitive function), and they have psychometric limitations as weft. Based on analyses of pooled data from natural history studies and from placebo groups in clinical trials, the National MS Society's Clinical Outcomes Assessment Task Force recently proposed a new multidimensional clinical outcome measure, the MS Functional Composite (MSFC). The MSFC comprises quantitative functional measures of three key clinical dimensions of MS: leg functional ambulation, arm/hand function, and cognitive function. scores on component measures are converted to standard scores (z-scores), which ore averaged to form a single MSFC score. Preliminary analyses confirm that (1) the three clinical dimensions of the MSFC are relatively independent; (2) the MSFC is sensitive to clinical changes over 1- and 2-year intervals; and (3) the MSFC has acceptable criterion validity (i.e, predicts both concurrent and subsequent EDSS change). The advantages and potential limitations of incorporating quantitative functional outcome measures such as the MSFC into collaborative databases are discussed.
引用
收藏
页码:244 / 250
页数:7
相关论文
共 25 条
  • [1] [Anonymous], 1999, Administration and scoring manual for the multiple sclerosis functional composite measure (MSFC)
  • [2] Bever C T Jr, 1995, Mult Scler, V1, P165
  • [3] Brooks Benjamin Rix, 1994, P131
  • [4] COOK SD, 1986, LANCET, V1, P1405
  • [5] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    [J]. BRAIN, 1999, 122 : 871 - 882
  • [6] A PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-MASKED, VARIABLE DOSAGE, CLINICAL-TRIAL OF AZATHIOPRINE WITH AND WITHOUT METHYLPREDNISOLONE IN MULTIPLE-SCLEROSIS
    ELLISON, GW
    MYERS, LW
    MICKEY, MR
    GRAVES, MC
    TOURTELLOTTE, WW
    SYNDULKO, K
    HOLEVOETHOWSON, MI
    LERNER, CD
    FRANE, MV
    PETTLERJENNINGS, P
    [J]. NEUROLOGY, 1989, 39 (08) : 1018 - 1026
  • [7] FISCHER JS, NEUROLOGY, V52, pA50
  • [8] GOLDSMITH CH, 1993, J RHEUMATOL, V20, P575
  • [9] LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS
    GOODKIN, DE
    RUDICK, RA
    MEDENDORP, SV
    DAUGHTRY, MM
    SCHWETZ, KM
    FISCHER, J
    VANDYKE, C
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (01) : 30 - 40
  • [10] GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850